A Colorado federal judge has just made it a little tougher for biopharma companies to get pretrial injunctions based on trade secret allegations.

Judge Philip Brimmer on Wednesday turned away Array BioPharma’s attempt to immediately stop nine former employees from working with former collaboration partner Loxo Oncology Inc. Without evidence that the partnership has produced a drug ready for clinical trials, there were no grounds for an injunction. “Irreparable harm that may occur years in the future, and certainly not before a trial on the merits, does not warrant injunctive relief,” Brimmer wrote.